A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage
Comparison of two combination chemotherapies in the treatment of patients with SLCL
Small Cell Lung Cancer
DRUG: Carboplatin plus Irinotecan vs Carboplatin plus Etoposide
Primary Endpoint:|Documentation of the remission rate ( Phase II)|Determination of progress free time (Phase III)
Secondary Endpoint:|Documentation of progress free time (Phase II)|Documentation of objective remission rate ( Phase III)|Documentation of 1-year survival rate|Documentation of safety of the drug combination
Comparison of two combination chemotherapies in the treatment of patients with SLCL

The combination chemotherapies for this study are Carboplatin plus Irinotecan versus Carboplatin plus Etoposide.